Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
5.81
-0.56 (-8.79%)
At close: Dec 5, 2025, 4:00 PM EST
5.87
+0.06 (1.03%)
After-hours: Dec 5, 2025, 7:29 PM EST
Abpro Holdings Revenue
In the year 2024, Abpro Holdings had annual revenue of $183.00K with 50.00% growth.
Revenue (ttm)
$183.00K
Revenue Growth
+50.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
15.78M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABP News
- 4 weeks ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 4 weeks ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 7 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 9 months ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire
- 9 months ago - Abpro Statement on the Departure of Former CEO Ian Chan - GlobeNewsWire
- 1 year ago - Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing - GlobeNewsWire